Details of the Drug

General Information of Drug (ID: DM2R68E)

• Drug Name: Ramipril
• Synonyms: Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]

Indication

Disease Entry	ICD 11	Status	REF
Congestive heart failure	BD10	Approved	[1], [2]

• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 416.5
  Topological Polar Surface Area (xlogp); 1.4
  Rotatable Bond Count (rotbonds); 10
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Elimination: 1.5% of drug is excreted from urine in the unchanged form [3]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.686 micromolar/kg/day [4]
• Chemical Identifiers:
  Formula: C23H32N2O5
  IUPAC Name: (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
  Canonical SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
  InChI: InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
  InChIKey: HDACQVRGBOVJII-JBDAPHQKSA-N
• Cross-matching ID:
  PubChem CID: 5362129
  ChEBI ID: CHEBI:8774
  CAS Number: 87333-19-5
  DrugBank ID: DB00178
  TTD ID: D01STB
  VARIDT ID: DR00031
  INTEDE ID: DR2648
  ACDINA ID: D00582

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin-converting enzyme (ACE)	TTL69WB	ACE_HUMAN	Inhibitor	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 2 (SLC15A2)	DT8QKNP	S15A2_HUMAN	Substrate	[6]
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[6]

Molecular Expression Atlas of This Drug

• The Studied Disease: Congestive heart failure
• ICD Disease Classification: BD10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Angiotensin-converting enzyme (ACE)	DTT	SLC33A1	2.62E-01	-0.01	-0.06
Peptide transporter 1 (SLC15A1)	DTP	PEPT1	6.91E-01	8.30E-03	7.24E-02
Peptide transporter 2 (SLC15A2)	DTP	PEPT2	8.33E-02	-3.63E-02	-1.27E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ramipril

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Spironolactone	DM2AQ5N	Major	Increased risk of hyperkalemia by the combination of Ramipril and Spironolactone.	Heart failure [BD10-BD1Z]	[30]
Triamterene	DM2HU9I	Major	Increased risk of hyperkalemia by the combination of Ramipril and Triamterene.	Heart failure [BD10-BD1Z]	[30]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Ramipril and Prazosin.	Heart failure [BD10-BD1Z]	[31]
Eplerenone	DMF0NQR	Moderate	Increased risk of hyperkalemia by the combination of Ramipril and Eplerenone.	Heart failure [BD10-BD1Z]	[32]
Chlorothiazide	DMLHESP	Moderate	Additive hypotensive effects by the combination of Ramipril and Chlorothiazide.	Heart failure [BD10-BD1Z]	[33]
Furosemide	DMMQ8ZG	Moderate	Additive hypotensive effects by the combination of Ramipril and Furosemide.	Heart failure [BD10-BD1Z]	[33]
Digoxin	DMQCTIH	Moderate	Decreased renal excretion of Ramipril caused by Digoxin.	Heart failure [BD10-BD1Z]	[34]
Amiloride	DMRTSGP	Major	Increased risk of hyperkalemia by the combination of Ramipril and Amiloride.	Heart failure [BD10-BD1Z]	[30]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Ramipril and Bumetanide.	Heart failure [BD10-BD1Z]	[33]
Hydroflumethiazide	DMVPUQI	Moderate	Additive hypotensive effects by the combination of Ramipril and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[33]
Torasemide	DMXKJ6C	Moderate	Additive hypotensive effects by the combination of Ramipril and Torasemide.	Heart failure [BD10-BD1Z]	[35]

Coadministration of a Drug Treating the Disease Different from Ramipril (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[36]
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Ramipril due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[37]
Glimepiride	DM5FSJA	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Glimepiride.	Acute diabete complication [5A2Y]	[38]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Repaglinide.	Acute diabete complication [5A2Y]	[38]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Glibenclamide.	Acute diabete complication [5A2Y]	[38]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Tolazamide.	Acute diabete complication [5A2Y]	[38]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Nateglinide.	Acute diabete complication [5A2Y]	[38]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Insulin-glulisine.	Acute diabete complication [5A2Y]	[38]
Acetohexamide	DMR6N7H	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Acetohexamide.	Acute diabete complication [5A2Y]	[38]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Insulin-aspart.	Acute diabete complication [5A2Y]	[39]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Glipizide.	Acute diabete complication [5A2Y]	[38]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Thioguanine.	Acute myeloid leukaemia [2A60]	[40]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[41]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Ramipril and Promazine.	Appearance/behaviour symptom [MB23]	[42]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Ramipril and Linezolid.	Bacterial infection [1A00-1C4Z]	[43]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Ramipril and Cariprazine.	Bipolar disorder [6A60]	[42]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Ramipril and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[44]
Mannitol	DMSCDY9	Moderate	Additive hypotensive effects by the combination of Ramipril and Mannitol.	Bronchiectasis [CA24]	[33]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Ramipril and Olopatadine.	Conjunctiva disorder [9A60]	[45]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Ramipril and Drospirenone.	Contraceptive management [QA21]	[46]
Ardeparin	DMYRX8B	Moderate	Increased risk of hyperkalemia by the combination of Ramipril and Ardeparin.	Coronary thrombosis [BA43]	[47]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Ramipril and Isocarboxazid.	Depression [6A70-6A7Z]	[43]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Ramipril and OPC-34712.	Depression [6A70-6A7Z]	[42]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Ramipril and Phenelzine.	Depression [6A70-6A7Z]	[43]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Ramipril and Nitroglycerin.	Diabetic foot ulcer [BD54]	[48]
SODIUM CITRATE	DMHPD2Y	Minor	Decreased absorption of Ramipril due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[37]
Diazepam	DM08E9O	Moderate	Additive hypotensive effects by the combination of Ramipril and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[49]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Cannabidiol.	Epileptic encephalopathy [8A62]	[50]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Ramipril and Ethacrynic acid.	Essential hypertension [BA00]	[35]
Bendroflumethiazide	DM7EVLC	Moderate	Additive hypotensive effects by the combination of Ramipril and Bendroflumethiazide.	Essential hypertension [BA00]	[33]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Ramipril and Phenoxybenzamine.	Essential hypertension [BA00]	[31]
Benzthiazide	DMQWZ0H	Moderate	Additive hypotensive effects by the combination of Ramipril and Benzthiazide.	Essential hypertension [BA00]	[33]
Acetazolamide	DM1AF5U	Moderate	Additive hypotensive effects by the combination of Ramipril and Acetazolamide.	Glaucoma [9C61]	[33]
Methazolamide	DM7J2TA	Moderate	Additive hypotensive effects by the combination of Ramipril and Methazolamide.	Glaucoma [9C61]	[33]
Dichlorphenamide	DMH7IDQ	Moderate	Additive hypotensive effects by the combination of Ramipril and Dichlorphenamide.	Glaucoma [9C61]	[35]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Ramipril and Procarbazine.	Hodgkin lymphoma [2B30]	[43]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[51]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Didanosine	DMI2QPE	Minor	Decreased absorption of Ramipril due to altered gastric pH caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Ramipril and Isosorbide mononitrate.	Hydrocephalus [8D64]	[48]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Ramipril and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[53]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Ramipril and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[54]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Ramipril and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[55]
Eprosartan	DM07K2I	Major	Increased risk of hyperkalemia by the combination of Ramipril and Eprosartan.	Hypertension [BA00-BA04]	[47]
Aliskiren	DM1BV7W	Major	Increased risk of hyperkalemia by the combination of Ramipril and Aliskiren.	Hypertension [BA00-BA04]	[56]
Losartan	DM72JXH	Major	Increased risk of hyperkalemia by the combination of Ramipril and Losartan.	Hypertension [BA00-BA04]	[47]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Ramipril and Doxazosin.	Hypertension [BA00-BA04]	[31]
Diltiazem	DMAI7ZV	Minor	Additive hypotensive effects by the combination of Ramipril and Diltiazem.	Hypertension [BA00-BA04]	[57]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Ramipril and TAK-491.	Hypertension [BA00-BA04]	[47]
Indapamide	DMGN1PW	Moderate	Additive hypotensive effects by the combination of Ramipril and Indapamide.	Hypertension [BA00-BA04]	[33]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Ramipril and Trichlormethiazide.	Hypertension [BA00-BA04]	[33]
Telmisartan	DMS3GX2	Major	Increased risk of hyperkalemia by the combination of Ramipril and Telmisartan.	Hypertension [BA00-BA04]	[58]
Irbesartan	DMTP1DC	Major	Increased risk of hyperkalemia by the combination of Ramipril and Irbesartan.	Hypertension [BA00-BA04]	[58]
Hydrochlorothiazide	DMUSZHD	Moderate	Additive hypotensive effects by the combination of Ramipril and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[33]
Potassium chloride	DMMTAJC	Major	Increased risk of hyperkalemia by the combination of Ramipril and Potassium chloride.	Hypo-kalaemia [5C77]	[33]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hyperkalemia by the combination of Ramipril and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[59]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Ramipril and Propiomazine.	Insomnia [7A00-7A0Z]	[42]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Ramipril and ITI-007.	Insomnia [7A00-7A0Z]	[42]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Methotrexate.	Leukaemia [2A60-2B33]	[50]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Ramipril and Porfimer Sodium.	Lung cancer [2C25]	[60]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[61]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Idelalisib.	Mature B-cell leukaemia [2A82]	[62]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Clofarabine.	Mature B-cell lymphoma [2A85]	[63]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Ramipril due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[54]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Ramipril and Ozanimod.	Multiple sclerosis [8A40]	[43]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Ramipril and Prochlorperazine.	Nausea/vomiting [MD90]	[42]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Ramipril and Promethazine.	Nausea/vomiting [MD90]	[42]
Thiethylperazine	DMU3IET	Moderate	Additive hypotensive effects by the combination of Ramipril and Thiethylperazine.	Nausea/vomiting [MD90]	[42]
Chlorthalidone	DM4DMBT	Moderate	Additive hypotensive effects by the combination of Ramipril and Chlorthalidone.	Oedema [MG29]	[33]
Metolazone	DMB39LO	Moderate	Additive hypotensive effects by the combination of Ramipril and Metolazone.	Oedema [MG29]	[33]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Ramipril and Polythiazide.	Oedema [MG29]	[33]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Ramipril and Safinamide.	Parkinsonism [8A00]	[43]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Ramipril and Rasagiline.	Parkinsonism [8A00]	[43]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Ramipril and Terazosin.	Prostate hyperplasia [GA90]	[31]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Ramipril and Silodosin.	Prostate hyperplasia [GA90]	[31]
Alfuzosin	DMZVMKF	Moderate	Additive hypotensive effects by the combination of Ramipril and Alfuzosin.	Prostate hyperplasia [GA90]	[31]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Ramipril and Levomepromazine.	Psychotic disorder [6A20-6A25]	[42]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Ramipril and Fluphenazine.	Psychotic disorder [6A20-6A25]	[42]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Ramipril and Leflunomide.	Rheumatoid arthritis [FA20]	[54]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Ramipril and Quetiapine.	Schizophrenia [6A20]	[42]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Ramipril and Mesoridazine.	Schizophrenia [6A20]	[42]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Ramipril and Iloperidone.	Schizophrenia [6A20]	[42]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Ramipril and Paliperidone.	Schizophrenia [6A20]	[42]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Ramipril and Loxapine.	Schizophrenia [6A20]	[42]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Ramipril and Haloperidol.	Schizophrenia [6A20]	[42]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Ramipril and Perphenazine.	Schizophrenia [6A20]	[42]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Ramipril and Molindone.	Schizophrenia [6A20]	[42]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Ramipril and Chlorpromazine.	Schizophrenia [6A20]	[42]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Ramipril and Thiothixene.	Schizophrenia [6A20]	[42]
Clozapine	DMFC71L	Moderate	Additive hypotensive effects by the combination of Ramipril and Clozapine.	Schizophrenia [6A20]	[42]
Ziprasidone	DMM58JY	Moderate	Additive hypotensive effects by the combination of Ramipril and Ziprasidone.	Schizophrenia [6A20]	[42]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Ramipril and Risperidone.	Schizophrenia [6A20]	[42]
Olanzapine	DMPFN6Y	Moderate	Additive hypotensive effects by the combination of Ramipril and Olanzapine.	Schizophrenia [6A20]	[42]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Ramipril and Amisulpride.	Schizophrenia [6A20]	[42]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Ramipril and Asenapine.	Schizophrenia [6A20]	[42]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[50]
Epirubicin	DMPDW6T	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[36]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Ramipril and Naltrexone.	Substance abuse [6C40]	[64]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of hyperkalemia by the combination of Ramipril and Tacrolimus.	Transplant rejection [NE84]	[65]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[38]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[38]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[38]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Ramipril and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[38]
Trimethoprim	DMM7CHK	Major	Increased risk of hyperkalemia by the combination of Ramipril and Trimethoprim.	Urinary tract infection [GC08]	[66]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Ramipril and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[42]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Ramipril and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[67]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Meglumine	E00181	8567	Buffering agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium oxide	E00232	14792	Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ramipril 10 mg capsule	10 mg	Oral Capsule	Oral
Ramipril 2.5 mg capsule	2.5 mg	Oral Capsule	Oral
Ramipril 1.25 mg capsule	1.25 mg	Oral Capsule	Oral
Ramipril 5 mg capsule	5 mg	Oral Capsule	Oral
Ramipril 2.5 mg tablet	2.5 mg	Oral Tablet	Oral
Ramipril 1.25 mg tablet	1.25 mg	Oral Tablet	Oral
Ramipril 5 mg tablet	5 mg	Oral Tablet	Oral
Ramipril 10 mg tablet	10 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6339).
• [2] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [3] BDDCS applied to over 900 drugs
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [6] Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
• [7] Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
• [8] Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
• [9] Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
• [10] High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
• [11] The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
• [12] Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
• [13] Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
• [14] Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
• [15] Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
• [16] The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
• [17] Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
• [18] Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
• [19] PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
• [20] Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
• [21] Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
• [22] Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
• [23] Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
• [24] Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
• [25] Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
• [26] Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
• [27] Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
• [28] Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
• [29] Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687.
• [30] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
• [31] Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
• [32] Product Information. Inspra (eplerenone). Searle, Chicago, IL.
• [33] Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
• [34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [35] Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
• [36] Cerner Multum, Inc. "Australian Product Information.".
• [37] Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
• [38] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [39] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
• [40] Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
• [41] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [42] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [43] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [44] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [45] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [46] Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
• [47] Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
• [48] Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
• [49] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595. [PMID: 9518913]
• [50] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [51] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [52] Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
• [53] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [54] Canadian Pharmacists Association.
• [55] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [56] Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
• [57] DeQuattro V "Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide." Clin Cardiol 14 (1991): iv28-32. [PMID: 1893639]
• [58] Product Information. Micardis (telmisartan). Boehringer-Ingelheim, Ridgefield, CT.
• [59] Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [60] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [61] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [62] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [63] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [64] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [65] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
• [66] Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438. [PMID: 8304666]
• [67] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.